Bifogade filer
Nanologica Publishes Prospectus in Connection with Rights Issue
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, SUBJECT TO LEGAL RESTRICTIONS OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES.
Nanologica AB (publ) (”Nanologica” or the “Company”) publishes a prospectus in connection with the rights issue of units corresponding to approximately SEK 99.4 million that was resolved by the board of directors on August 29, 2024 and that was approved by the extraordinary general meeting on September 23, 2024 (the “Rights Issue”).
Prospectus
The prospectus has been prepared in connection to the Rights Issue and has today, on September 26, 2024, been approved by the Swedish Financial Supervisory Authorithy. The prospectus, which contains complete terms and conditions for the Rights Issue, is available on the Company’s website (www.nanologica.com). The prospectus will also be available on the Swedish Financial Supervisory Authority’s website (www.fi.se). Subscription forms will be available on the Company’s and Bergs Securities AB’s respective websites.
Timetable for the Rights Issue
| 30 September - 14 October 2024 | Subscription period |
| 30 September - 9 October 2024 | Trading in unit rights |
| 30 September - 30 October 2024 | Trading in BTU |
| 16 October 2024 | Estimated day for announcement of the outcome of the Rights Issue |
Advisors
Nanologica has engaged Redeye AB as Joint Bookrunner, Bergs Securities AB as Joint Bookrunner and issuing agent, and Advokatfirman Lindahl KB as legal advisor in connection with the Rights Issue.